Most Recent

image: The Growth of Iowa Biotech

The Growth of Iowa Biotech

By | August 1, 2016

The state’s industry draws inspiration from medicine as well as agriculture.

1 Comment

image: Desperately Seeking Shut-Eye

Desperately Seeking Shut-Eye

By | March 1, 2016

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

0 Comments

image: Picking Up the Pace

Picking Up the Pace

By | January 1, 2016

FDA designations promise to expedite the approval of drugs for conditions ranging from infectious disease to cancer.

0 Comments

image: Battling the Bulge

Battling the Bulge

By | November 1, 2015

Weight-loss drugs that target newly characterized obesity-related receptors and pathways could finally offer truly effective fat control.

0 Comments

image: The Sounds of Silence

The Sounds of Silence

By | September 1, 2015

Science-based tinnitus therapeutics are finally coming into their own.

3 Comments

image: Clinical Matchmaker

Clinical Matchmaker

By | June 1, 2015

Enrolling the right patient population could be key to a successful clinical trial.

0 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: Cannabis Biotech

Cannabis Biotech

By | December 1, 2014

As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.

2 Comments

image: That Loving Feeling

That Loving Feeling

By | July 1, 2014

There are no FDA-approved drugs to treat low sexual desire in women, but not for lack of trying.

1 Comment

image: Incubator Boom

Incubator Boom

By | March 1, 2014

From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?  

2 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech